Evidence map›Paper›PMID 32864095›Full record

ArticleClinical sarcoma research2020

Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary.

Eve Merry, Alannah Smrke, Kapil Halai, Gulam Patel, Khin Thway, Robin L Jones, Charlotte Benson

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Clinical sarcoma research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Eve MerrySarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ UK.
Alannah SmrkeSarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ UK.
Kapil HalaiRheumatology Department, Ashford and St Peter's NHS Hospitals NHS Foundation Trust, London, TW15 3AA UK.
Gulam PatelRheumatology Department, Ashford and St Peter's NHS Hospitals NHS Foundation Trust, London, TW15 3AA UK.
Khin ThwaySarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ UK.
Robin L JonesSarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ UK.
Charlotte BensonSarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ UK.
Ashford and St Peter's Hospitals NHS Foundation Trust · GBRoyal Marsden Hospital · GBRoyal Marsden NHS Foundation Trust · GBInstitute of Cancer Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcomas are rare and heterogeneous tumours of mesenchymal origin, with over 100 histological subtypes. Paraneoplastic dermatomyositis has rarely been described in sarcoma. This is the first documented case of paraneoplastic dermatomyositis in a patient with metastatic leiomyosarcoma. CASE PRESENTATION: A 43-year-old female diagnosed with metastatic leiomyosarcoma of unknown primary presented with a mild rash in sun-exposed areas of her face and upper chest, with no other neuromuscular symptoms. This rash resolved with systemic treatment with doxorubicin for metastatic leiomyosarcoma. Imaging assessment confirmed overall stable disease after chemotherapy completion. She presented acutely 2 months later with new onset rash in a shawl-like distribution, periorbital oedema and proximal muscle weakness. Based on the characteristic cutaneous signs and symmetrical proximal muscle weakness, abnormal electromyography and raised skeletal muscle enzymes with a positive anti-transcription intermediary factor-1 gamma antibody result, a diagnosis of paraneoplastic dermatomyositis was made. Re-evaluation of her metastatic leiomyosarcoma revealed disease progression. Second-line chemotherapy was commenced once the dermatomyositis was controlled on steroid therapy. Systemic anti-cancer therapy was again associated with mild improvement in dermatomyositis symptoms. DISCUSSION: Paraneoplastic dermatomyositis heralded disease progression after first-line chemotherapy; however, in hindsight, subtle cutaneous features were present at sarcoma diagnosis. The temporal relationship between paraneoplastic dermatomyositis and metastatic leiomyosarcoma is key in this case, as fluctuations in dermatomyositis severity correlated with growth of metastatic disease. Understanding this relationship may provide clues for tumour progression and prompt timely initiation of anti-cancer therapy. It is important to recognise that in addition to the more common cancers associated with paraneoplastic dermatomyositis, it can also occur in rarer tumours such as leiomyosarcoma.

Indexed as

ChemotherapyDermatomyositisLeiomyosarcomaParaneoplasticSoft tissue sarcomaTIF1γ antibody

Identifiers

PMID32864095
PMCPMC7448307
OpenAlexW3080417607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.